Key clinical point: Desvenlafaxine improves symptom clusters in major depressive disorder (MDD), with early improvement predicting remission.
Major finding: Desvenlafaxine 50 mg and 100 mg was associated with significant improvement for all symptom clusters in MDD (P less than .001), except a sleep cluster for desvenlafaxine 100 mg. An early improvement was a predictor of symptomatic or functional remission at week 8 (P less than or equal to .0254).
Study details: A pooled analysis of nine double-blind, placebo-controlled studies that assessed the effects of desvenlafaxine 50 mg and 100 mg vs. placebo for the symptom clusters of MDD.
Disclosures: The study was funded by Pfizer, Inc. The corresponding author reported financial interests/affiliations with multiple pharmaceutical companies, including Pfizer. One of the authors was an employee of Pfizer Canada, Inc at the time of the study and owns Pfizer stock. Another author is a full-time employee of Pfizer and owns Pfizer stocks and options.
Katzman MA et al. J Psychopharmacol. 2020 Jan 8. doi: 10.1177/0269881119896066.